A5078163245- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- RNA modifications and cancer
- Multiple Myeloma Research and Treatments
- Epigenetics and DNA Methylation
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- COVID-19 and healthcare impacts
- Cancer, Lipids, and Metabolism
- Hematological disorders and diagnostics
- Economic and Financial Impacts of Cancer
- Cancer therapeutics and mechanisms
- Science, Research, and Medicine
AZ Klina
2015-2025
Antwerp University Hospital
2021
Universitair Ziekenhuis Brussel
2020
Belgian Society of Medical Oncology
2014
Cancer Institute (WIA)
2007
Universitair Ziekenhuis Leuven
2006
Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall are limited by resistance.
The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.
Epidemiological changes and the ongoing expansion of diagnostic armamentarium warrant a regular update spectrum diseases that present as prolonged febrile illnesses.We prospectively collected series 290 immunocompetent patients referred to our university hospital between 1990 1999 with illness (temperature >38.3 degrees C) uncertain cause, lasting at least 3 weeks. Patients were categorized in 4 groups according timing diagnosis: early diagnosis (within in-hospital days or outpatient...
Abstract Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line AR signaling inhibitors (ARSi). Experimental Design: Between March 2014 April 2017, we recruited mCRPC (n = 168) prior to ARSi cohort study encompassing 10 European centers. Blood samples were collected for comprehensive CellSearch-enriched circulating tumor cells (CTC) DNA...
There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need predictive biomarkers. Circulating tumor DNA (ctDNA) has potential to cost-efficiently accelerate precision medicine trials improve clinical efficacy diminish costs toxicity. However, comprehensive ctDNA profiling in cancer date been limited. A combination of targeted low-pass whole genome sequencing was performed on plasma cell-free matched white blood...
LBA1 Background: Platinum-based chemotherapy is an active 1L regimen for advanced UC; however, progression-free survival (PFS) and overall (OS) are generally short because of resistance. This randomized, phase 3 trial (JAVELIN Bladder 100; NCT02603432) evaluated avelumab (anti–PD-L1) as maintenance therapy following response or stable disease with platinum-based in patients UC. Methods: Eligible unresectable locally metastatic UC without progression after 4-6 cycles gemcitabine either...
The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients small cell lung cancer (SCLC).
Cancer seems to have an independent adverse prognostic effect on COVID-19-related mortality, but uncertainty exists regarding its across different patient subgroups. We report a population-based analysis of patients hospitalised with COVID-19 prior or current solid cancer versus those without cancer.We analysed data adult registered until 24 May 2020 in the Belgian nationwide database Sciensano. The primary objective was in-hospital mortality within 30 days diagnosis among cancer. Severe...
474 Background: In the JAVELIN Renal 101 phase 3 trial, 1L avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib patients with aRCC, an acceptable safety profile. The AVION study is evaluating effectiveness of routine clinical practice various countries. We report data from primary analysis. Methods: prospective noninterventional aRCC receiving Germany, Greece, Belgium, or Russia. Patients are observed for...
The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence anti-S1 antibodies (IgGs) in cancer patients is still understudied. This work examines existence an immunoglobulin G (IgG) -based correlate (CoP) established prospectively collected observational data about with different variants a large cohort study vaccinated patients. 760 were longitudinally followed-up, starting before first vaccination until six months after second booster. Anti-S1 IgGs...
Abstract Background Research on the relationship between hospital volume and quality of care in treatment rectal cancer is limited. Methods Process outcome indicators were assessed patients with adenocarcinoma who underwent total mesorectal excision, registered a voluntary basis PROCARE clinical database. Volume was derived from an administrative database analysed as continuous variable. Sphincter preservation, 30-day mortality survival rates cross-checked against population-based data....
Abstract Purpose: Analysis of methylation markers in liquid biopsies is a promising technique for the follow-up patients with metastatic colorectal cancer (mCRC), because they can be used all patients, regardless their mutational status. Therefore, we studied value NPY analysis circulating tumor DNA (ctDNA) accurate response monitoring mCRC PANIB trial. Experimental Design: The trial was randomized phase II designed to compare FOLFOX plus panitumumab and bevacizumab RAS wild-type...
Background The outcome to treatment administered patients with metastatic castration‐resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding decision making. Objective To investigate prognostic value of circulating tumor cell (CTC) enumeration and dynamics, in context second‐line endocrine therapies (ie, abiraterone acetate or enzalutamide), irrespective prior systemic therapies. Design, Settings, Participants In a prospective,...
Fluoropyrimidines such as 5-Fluorouracil (5-FU), capecitabine and tegafur are drugs that often used in the treatment of maliginancies. The enzyme dihydropyrimidine dehydrogenase (DPD) is first rate limiting 5-FU catabolism. Genetic variations within DPYD gene (encoding for DPD protein) can lead to reduced or absent activity. Treatment deficient patients with fluoropyrimidines result severe and, rarely, fatal toxicity. Screening deficiency should be implemented practice.The available methods...
Low- to intermediate-grade chondrosarcoma is usually a slow-growing and highly chemotherapyresistant tumor type. Case Report: The 76-year-old female patient presented with low- of the distal phalanx right thumb in 1993 was treated an excision carpometacarpal joint. Approximately 10 years later, recurrent local disease at trapezoid bone, which resected. Eight months later she recurrence carpal joint lung metastases. Subsequently chemotherapeutically pegylated liposomal doxorubicin as part...